Insider Selling: Dyne Therapeutics (NASDAQ:DYN) CEO Sells $106,823.04 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) CEO John Cox sold 5,658 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total transaction of $106,823.04. Following the sale, the chief executive officer directly owned 357,507 shares in the company, valued at $6,749,732.16. This trade represents a 1.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dyne Therapeutics Trading Down 16.4%

Shares of Dyne Therapeutics stock traded down $3.97 on Tuesday, hitting $20.31. 17,066,387 shares of the company’s stock traded hands, compared to its average volume of 2,151,348. Dyne Therapeutics, Inc. has a one year low of $11.92 and a one year high of $27.31. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The company has a fifty day moving average of $24.86 and a two-hundred day moving average of $20.45. The company has a market capitalization of $3.79 billion, a price-to-earnings ratio of -6.10 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current year.

Institutional Trading of Dyne Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC bought a new stake in Dyne Therapeutics during the 1st quarter valued at approximately $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Dyne Therapeutics by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after purchasing an additional 2,886 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Dyne Therapeutics by 58.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after buying an additional 366,183 shares during the last quarter. Caxton Associates LLP purchased a new stake in Dyne Therapeutics during the first quarter valued at $157,000. Finally, Creative Planning increased its position in shares of Dyne Therapeutics by 23.8% during the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after purchasing an additional 2,797 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on DYN shares. Wall Street Zen cut shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Raymond James Financial reiterated a “strong-buy” rating and set a $37.00 target price on shares of Dyne Therapeutics in a research note on Tuesday. Sanford C. Bernstein upped their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Monday, August 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.